ThomsenHS.Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol2006; 16(12): 2619–2621.
2.
WangYAlkasabTKNarinO, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology2011; 260(1): 105–111.
3.
KandaTIshiiKKawaguchiH, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: Relationship with increasing cumulative dose of a gadolinium based contrast material. Radiology2014; 270(3): 834–841.
4.
DekkersIARoosRvan der MolenAJ.Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol2018; 28(4): 1579–1584.
RoviraAWattjesMPTintoreM, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol2015; 11(8): 471–482.
7.
SormaniMPBruzziP.MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol2013; 12(7): 669–676.
8.
RíoJAugerCRoviraÀ.MR imaging in monitoring and predicting treatment response in multiple sclerosis. Neuroimaging Clin N Am2017; 27(2): 277–287.
9.
WattjesMPRoviraÀMillerD, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11(10): 597–606.
10.
EichingerPSchönSPongratzV, et al. Accuracy of unenhanced MRI in the detection of new brain lesions in multiple sclerosis. Radiology2019; 291(2): 429–435.
